Stonegate Capital Partners has updated its coverage on NU Skin Enterprises Inc. (NYSE: NUS), following the company's fourth-quarter 2025 earnings report. The report, released on February 13, 2026, details NUS's performance and strategic initiatives. NUS reported revenue of $370.3 million, adjusted net income of $14.5 million, and adjusted earnings per share of $0.29. These results were at the low end of revenue guidance but the high end of EPS guidance, reflecting disciplined cost management and strategic execution.
Revenue from the Rhyz segment totaled $48.52 million, comprising $42.45 million from Manufacturing and $6.07 million from Rhyz Other. The Nu Skin core business maintained a gross margin of 77.6%, while selling expenses declined to 40.8% of the core business, underscoring the company's focus on operational efficiency. Management attributed the EPS performance to strategic penetration into emerging markets, particularly India, along with overall margin expansion and a one-time tax benefit.
Key strategic updates include the ongoing rollout of Prism iO, expected to advance in the first half of 2026, and the pre-launch phase in India, with a full market opening anticipated in the second half of 2026. These initiatives are central to NUS's growth strategy. The company also provided fiscal year 2026 EPS guidance with a midpoint of $1.00, signaling confidence in its trajectory despite challenging top-line conditions.
The full announcement, including downloadable images and bios, is available here. Stonegate Capital Partners, a leading capital markets advisory firm, provides investor relations, equity research, and institutional investor outreach services. For more information, visit Stonegate's website.
This update is important for investors as it highlights NUS's ability to manage costs and execute strategic initiatives in a challenging revenue environment, while also providing visibility into upcoming growth drivers such as the India market launch and Prism iO rollout.
